What is Predominantly large-vessel vasculitis?
Predominantly large-vessel vasculitis is a group of rare inflammatory disorders that primarily affect the aorta and its major branches, though other arteries may also be involved. This category, as classified by Orphanet (ORPHA:156140), encompasses conditions such as Takayasu arteritis and giant cell arteritis (also known as temporal arteritis), which are the two principal forms. These diseases are characterized by inflammation of the walls of large arteries, leading to vessel wall thickening, stenosis (narrowing), occlusion, or aneurysm formation. The inflammatory process can compromise blood flow to vital organs and limbs. Clinical features vary depending on the specific condition and the vessels involved but commonly include systemic symptoms such as fatigue, fever, weight loss, and elevated inflammatory markers. Patients may experience limb claudication (pain with use due to reduced blood flow), absent or diminished pulses, blood pressure discrepancies between limbs, headaches, jaw claudication, and visual disturbances. Giant cell arteritis predominantly affects individuals over 50 years of age and carries a risk of irreversible vision loss if untreated, while Takayasu arteritis typically presents in younger women. Aortic aneurysms and aortic regurgitation are serious complications of both conditions. Treatment is primarily based on immunosuppression. Glucocorticoids remain the cornerstone of initial therapy for both Takayasu arteritis and giant cell arteritis. Steroid-sparing agents such as methotrexate, azathioprine, and mycophenolate mofetil are frequently used. More recently, biologic therapies including tocilizumab (an interleukin-6 receptor inhibitor) have been approved for giant cell arteritis and are used in refractory Takayasu arteritis. Vascular interventions, including angioplasty or surgical bypass, may be necessary for critical stenoses or aneurysms. Long-term monitoring with imaging and inflammatory markers is essential to detect disease relapse and progression.
- Inheritance
- Multifactorial
- Caused by a mix of several genes and environmental factors
- Age of Onset
- Variable
- Can begin at different ages, from infancy through adulthood
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for Predominantly large-vessel vasculitis.
View clinical trials →Clinical Trials
View all trials with filters →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
No actively recruiting trials found for Predominantly large-vessel vasculitis at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
No specialists are currently listed for Predominantly large-vessel vasculitis.
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to Predominantly large-vessel vasculitis.
Community
No community posts yet. Be the first to share your experience with Predominantly large-vessel vasculitis.
Start the conversation →Latest news about Predominantly large-vessel vasculitis
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for Predominantly large-vessel vasculitis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Predominantly large-vessel vasculitis
What is Predominantly large-vessel vasculitis?
Predominantly large-vessel vasculitis is a group of rare inflammatory disorders that primarily affect the aorta and its major branches, though other arteries may also be involved. This category, as classified by Orphanet (ORPHA:156140), encompasses conditions such as Takayasu arteritis and giant cell arteritis (also known as temporal arteritis), which are the two principal forms. These diseases are characterized by inflammation of the walls of large arteries, leading to vessel wall thickening, stenosis (narrowing), occlusion, or aneurysm formation. The inflammatory process can compromise blood
How is Predominantly large-vessel vasculitis inherited?
Predominantly large-vessel vasculitis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Frequently asked questions about Predominantly large-vessel vasculitis
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is Predominantly large-vessel vasculitis?
Predominantly large-vessel vasculitis is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:156140). It is typically inherited as multifactorial. Age of onset is generally variable. For verified primary sources, see the UniteRare Predominantly large-vessel vasculitis page.
How is Predominantly large-vessel vasculitis inherited?
Predominantly large-vessel vasculitis follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for Predominantly large-vessel vasculitis?
Approved treatments for Predominantly large-vessel vasculitis are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials for Predominantly large-vessel vasculitis?
Active clinical trials for Predominantly large-vessel vasculitis are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.
How do I find a specialist for Predominantly large-vessel vasculitis?
Verified Predominantly large-vessel vasculitis specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.
See full Predominantly large-vessel vasculitis page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.